AbbVie cures STING fever with Mavupharma acquisition pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
Stock Market | Daily Herald dailyherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyherald.com Daily Mail and Mail on Sunday newspapers.
Published: Jun 09, 2021 By Mark Terry
Kojin Therapeutics
launched with a $60 million Series A to initially focus on oncology and cell state biology. The round was led by Polaris Partners, Newpath Partners, and Cathay Health, affiliated to Cathay Capital. Participants included Leaps by Bayer, AbbVie, Eventide Asset Management, Alexandria, the Dana-Farber Cancer Institute’s Binney Street Capital, and several family offices.
The approach came out of the
laboratoryof Stuart Schreiber, Harvard University professor and co-founder of the Broad Institute. Co-founders of Kojin include Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan. The company’s technology is ferroptosis-based drug discovery, which is to say, iron-dependent cell death. Kojin says that difficult-to-treat diseases, which includes drug-resistant cancers, involve diseased cells that are sensitive to ferroptosis.
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
ABBVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor -T cell therapeutics. Although allogeneic, “off-the-shelf” CAR-T cell therapies have shown early promise in some cancer patients, the need for overcoming the rejection …
– ABBVie (NYSE: ABBV) and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today that they have entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Although allogeneic, “off-the-shelf” CAR-T cell therapies have shown early promise in some cancer patients, the need for overcoming the rejection of allogeneic CAR-T c